SNCA and Alzheimer disease: Our IM group is a model of MCI [9], not AD, and to our knowledge, there is no characterisation of miR-153-3p in patients with MCI, leaving open the hypothesis that overexpression of this miRNA may represent an attempt to counteract the increasing levels of amyloid-beta and alpha-synuclein production at this stage.